Accelerate the delivery of
mRNA-based therapeutics
and vaccines to patients

Welcome to the mRNA-Based Therapeutics: Searchlight network

Built by the mRNA community for the mRNA community 

With the dozens of mRNA-based vaccine candidates currently in the pre-clinical and clinical phases of development, it is evident that the mRNA-based vaccine technology is a promising tool for developing novel therapeutic and prophylactic vaccines against infectious diseases and cancer. However, the multifarious obstacles associated with the likes of safety, efficacy, CMC aspects and general lack of guidance hamper the translation of mRNA-based therapeutics from the bench to the bedside. 

To address some of these challenges head-on, mRNA pioneers worldwide have created the mRNA-Based Therapeutics: Searchlight network. The networks’ sole purpose is to overcome critical challenges and bottlenecks in mRNA therapeutic and vaccine development to accelerate the delivery of therapies to patients. 

At the heart of Searchlight, we believe that innovation does not happen in isolation. Through the exchange of experiences and best practices, the network solves pressing issues faster than in isolation, saving time and money while increasing confidence in decision-making. 

Don’t miss out on the opportunity to be part of these critical conversations 

"Establishing the acceptable levels of contaminants such as the double stranded RNA (dsRNA) within mRNA drug products"

"How to align global regulatory and safety experience in mRNA as a platform technology"

"Understanding which animal model elicit the most transferrable response to humans"

Join your peers today and be part of a global community of like-minded individuals 

Searchlight - LEAP HR - Exec Summary lock up

Membership brochure

For more information on what’s included as part of the mRNA-Based Therapeutics: Searchlight membership, please download the membership brochure. 

Here’s what you’ll learn more about: 

  • The unique mission and purpose of the network 
  • What membership includes 
  • How the quarterly cornerstone meetings work 
  • How bespoke value delivery works 
  • How we deliver demonstrable value to you 
  • Annual member investment 

The feedback from members speaks for itself…

Jon Shanter, Director, Vaccine Process Development, Merck

“Regulatory opinions for mRNA will take time to stabilize but I’d expect the scope of this network to play an important role in accelerating that, which will mean getting better drugs to patients faster”

Theresa Goletz, Global Head Of Analytical Immunology & Cellular Platform, GSK

“This network offers us the valuable chance to discuss the things that don't appear in scientific publications as well as the chance to regularly engage with a trusted group of peers and see how the areas you’re interested in are evolving and advancing outside your company”

Ryan Shaler, Associate Director, Immunology & mRNA Discovery, Sonata Therapeutics

"It is so useful to have a sounding board of people doing the same work and facing the same challenges as us. Having a network like this will allow us to get answers faster than trying to muddle our way through it ourselves."

For more reviews about mRNA-Based Therapeutics: Searchlight membership, head to our testimonials page and hear directly from our members about why they've joined. 

Discover how we can provide you with demonstrable value…


Influence regulatory standards for mRNA-based therapeutics and vaccines and amplify your voice as part of a larger collective


Make better informed drug development decisions enabled by exclusive post-meeting reports to translate insights to your wider team


Save time and avoid dead ends by understand which animal models haven’t worked as well as approaches that have

Who qualifies for mRNA-Based Therapeutics: Searchlight Network?

Expert mRNA leaders

Member companies are represented by one internal champion who has strategic oversight over its mRNA program 

Motivated to collaborate 

Success relies on the equitable exchange of experience and a focus on what can be shared rather than being restricted by what can’t 

Experience to share 

Members must be able to contribute to a series of overlapping shared challenges across the drug development lifecycle